Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GSK's Zejula Poised To Take On Lynparza In First-Line Ovarian Cancer

Executive Summary

The Phase III PRIMA study in first-line ovarian cancer was positive for progression-free survival in patients regardless of their biomarker status, GSK reported.

You may also be interested in...



ESMO: Lynparza, Zejula Continue Rivalry With Long-Term Ovarian Maintenance Data

AstraZeneca/Merck’s Lynparza showed an OS benefit in first-line maintenance of ovarian cancer, but while data for Zejula were less mature, the GSK drug targets a broader population.

GSK Braces For A Hit To Its Vaccines Business Despite A Strong First Quarter

Stay-at-home restrictions due to COVID-19 have started to impact the company's vaccines business, including the big growth driver Shingrix.

ESMO Preview: Five Key Oncology Battlegrounds To Watch

GSK looks to become a cancer contender once again, while Merck and Roche go toe-to-toe in TNBC.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC125541

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel